RESP-X, Infex Therapeutics’ anti-virulence therapy to treat Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis bronchiectasis (NCFB) patients, has shown a promising interim safety and tolerability profile in its ongoing first-in-human Phase I clinical trial. The first cohort consisted of eight healthy volunteers who received doses of RESP-X at 1mg/kg. No serious adverse events were reported, […]